Compare
Orchestra BioMed Holdings, Inc. vs ClearPoint Neuro, Inc. vs Cytosorbents Corp vs Retractable Technologies Inc
| Latest fiscal year | Orchestra BioMed Holdings, Inc. OBIO | ClearPoint Neuro, Inc. CLPT | Cytosorbents Corp CTSO | Retractable Technologies Inc RVP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $33.48M | $36.97M | $37.06M | $38.27M |
| Revenue growth (YoY) | n/m | +17.8% | +4.1% | +15.8% |
| Gross margin | n/a | 61.4% | 71.5% | 0.1% |
| Operating margin | -154.7% | -65.4% | -39.8% | -55.3% |
| Net margin | -157.4% | -69.1% | -22.1% | -32.8% |
| Net income | -$52.70M | -$25.54M | -$8.20M | -$12.57M |
| EPS (Diluted) | -$1.11 | -$0.90 | -$0.13 | -$0.43 |
| Operating cash flow | -$48.96M | -$23.93M | -$12.38M | -$7.06M |
| Free cash flow | -$49.45M | -$24.45M | -$12.54M | n/a |
| Cash & equivalents | $34.69M | $45.92M | $6.25M | $2.59M |
| Total assets | $114.86M | $97.75M | $44.18M | $142.63M |
| Total liabilities | $51.48M | $69.73M | $38.28M | $68.26M |
| Shareholders' equity | $53.57M | $28.02M | $5.90M | $74.38M |
| Return on year-end equity | -98.4% | -91.1% | -138.9% | -16.9% |
| Shares outstanding | 57.03M | 29.37M | 62.80M | 29.94M |
Revenue, most recent five fiscal years
| Fiscal year | Orchestra BioMed Holdings, Inc. | ClearPoint Neuro, Inc. | Cytosorbents Corp | Retractable Technologies Inc |
|---|---|---|---|---|
| Latest | $33.48M Ended 2025-12-31 | $36.97M Ended 2025-12-31 | $37.06M Ended 2025-12-31 | $38.27M Ended 2025-12-31 |
| 1 year earlier | $2.64M Ended 2024-12-31 | $31.39M Ended 2024-12-31 | $35.59M Ended 2024-12-31 | $33.05M Ended 2024-12-31 |
| 2 years earlier | $2.76M Ended 2023-12-31 | $23.95M Ended 2023-12-31 | $31.08M Ended 2023-12-31 | $43.60M Ended 2023-12-31 |
| 3 years earlier | $3.53M Ended 2022-12-31 | $20.55M Ended 2022-12-31 | $34.69M Ended 2022-12-31 | $94.82M Ended 2022-12-31 |
| 4 years earlier | n/a | $16.30M Ended 2021-12-31 | $43.17M Ended 2021-12-31 | $188.38M Ended 2021-12-31 |